Skip to main content
Resverlogix Corp. logo

Resverlogix Corp. — Investor Relations & Filings

Ticker · RVX ISIN · CA76128M1086 LEI · 529900VI46SAPCOSH758 TSX Real estate activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2026-04-11 Regulatory Filings
Country CA Canada
Listing TSX RVX

About Resverlogix Corp.

https://www.resverlogix.com/

Resverlogix Corp. is a late-stage clinical biotechnology company specializing in the development of epigenetic therapies for chronic illnesses. The company's core scientific focus involves regulating the expression of disease-causing genes. Its lead drug candidate is Apabetalone, a small molecule inhibitor currently being advanced through clinical programs, including the BETonMACE trial. Apabetalone is primarily targeted toward treating cardiovascular diseases and complications associated with diabetes mellitus. Resverlogix aims to provide novel science and value-based health solutions to key stakeholders, including pharmaceutical companies, physicians, and health payer groups.

Recent filings

Filing Released Lang Actions
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 1% confidence The document is a completed OSC Form 13-502F1 (participation fee calculation) filed with the Ontario Securities Commission, detailing market values, fee calculations, and certification by an officer. It is not a full financial report (10-K, IR), not a shareholder notice (DIV, DVA), not an earnings release (ER), nor an investor presentation. It is an administrative regulatory submission under OSC Rule 13-502 Fees. This falls under the generic regulatory filings category (RNS).
2026-04-11 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is the Independent Auditor’s Report on the consolidated financial statements for the years ended December 31, 2025 and 2024, including the auditor’s opinion, basis for opinion, key audit matters, and management’s responsibility sections. It is a standalone audit report rather than a full annual report, earnings release, or other announcement. Therefore, it fits the Audit Report / Information (AR) category. FY 2025
2026-04-11 English
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 1% confidence The document is structured as an Independent Auditor’s Report to the shareholders, including audit opinions, key audit matters, management’s responsibility, and consolidated financial statements for the years ended December 31, 2025 and 2024. It lacks the broader narrative, risk factors, and full MD&A that would constitute a complete annual report. It is therefore a standalone audit report and financial statements, fitting the Audit Report / Information category. FY 2025
2026-04-11 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release announcing the issuance of a management cease trade order by the Alberta Securities Commission under NP 12-203. It is a regulatory event update rather than a financial report, earnings release, dividend notice, or capital raising. There is no indication of an AGM, annual or interim report, proxy materials, or share issue. Therefore, it falls under the fallback category for regulatory announcements: Regulatory Filings (RNS).
2026-04-02 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a press release providing a bi-weekly status update on a management cease trade order (MCTO) application under Canadian securities policy, not the actual annual filings or financial report. It is neither an annual report, earnings release, nor any other predefined category (e.g., board changes, dividends, or share issues). It is a miscellaneous regulatory announcement about continuous disclosure default status, best fitting the fallback “Regulatory Filings (RNS)” category.
2026-04-01 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of a new member to the company's board of directors. According to the filing definitions, announcements regarding changes in the board of directors or senior management fall under the 'MANG' (Board/Management Information) category.
2025-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.